India....In Pharma World.....

INDIA... In PharmaWorld....

The Indian pharmaceutical industry has contributed
immensely not just to Indian but to global healthcare
outcomes. India continues to play a significant role
in manufacturing various important, high‐quality and
cost-efficient medicines for Indian and global markets.

INDIA’S PRESENCE IN THE GLOBAL MARKET
India supplies over 50% of worldwide demand for
many vaccines, 40% of generic drugs consumed in the
US and 25% of all the medicines distributed in the UK.
India caters to 60% of global anti‐retroviral (ARV) drugs
and 30% of the annual UNICEF requirement. Affordable
ARV drugs from India were a major factor in AIDS
patients getting greater access to treatment.
Many Indian companies are co-partnering with foreign
voluntary organizations for making drugs available to
lesser developed countries like Mozambique, Rwanda,
South Africa and Tanzania which have about 33% of all
people living with AIDS in Africa.

OVERVIEW OF THE PHARMACEUTICALS
INDUSTRY IN INDIA

The annual turnover of the Indian pharmaceutical
industry is estimated to be about USD 33.8 Bn during
the year 2016-17. The Indian pharmaceuticals industry
has grown with an average annual growth rate of over
6% during the last 5 years, which is higher than the
global average growth rate.
Top Indian pharmaceutical companies have received
various international regulatory approvals for
their plants, from agencies like USFDA, MHRA-UK,
TGA-Australia, MCC-South Africa etc. Some of the
leading Indian pharmaceutical companies derive about
50% of their turnover from international business.
Pharmaceuticals exports have been consistently
growing for the last few years. The US and the EU
together account for over 90% of the regulated market
exports and close to 50% of formulation exports for
the domestic companies.

STRENGTHS AND FACTORS CONTRIBUTING
TO THIS GROWTH

Manufacturers’ strengths in Organic Chemical
Synthesis and Process Engineering: The
pharmaceuticals industry has shown tremendous
progress in terms of infrastructure development,technology base and a wide range of products. The
industry has developed excellent GMP Certified (Good
Manufacturing Practices) facilities for the production
of different dosage forms.
Low cost and large scale manufacturing capability in
India: India has the second highest number of USFDA
approved facilities and labour costs in India are lower
than other manufacturing hubs by up to 40%.
Stable growth in domestic market consumption:
Despite recent headwinds, India’s pharmaceutical
market has grown rapidly over the last decade. India
is likely to become one of the top 3 pharmaceutical
markets by 2030.
Increasing demand in global markets: Generic
penetration in high value healthcare markets (e.g., US)
has grown significantly, with India supplying over 20%
of the demand in major geographies.

-SIDDHANT PATIL,
F.Y.Pharm D, POONA COLLEGE of PHARMACY